Abstract

The evidence that BCG (bacille Calmette-Guerin) vaccine may increase the ability of the immune system to fight off pathogens other than tuberculosis has been studied in the past. This nonspecific immunity gained our interest, especially after initial reports of less cases in countries with universal BCG vaccination. In hopes of possible protective immunity, all staff of the Emirates International Hospital (United Arab Emirates) were offered a booster BCG vaccine in early March 2020. All the hospital staff were then tested for Covid-19 infection by the end of June 2020. We divided the subjects into two groups: booster vaccinated versus unvaccinated. The rate of Covid-19 infection was compared between the groups. Criteria included all staff who were offered the vaccine. Seventy-one subjects received the booster vaccination. This group had zero cases of positive COVID 19 infection. Two hundred nine subjects did not receive the vaccination, with 18 positive PCR confirmed COVID 19 cases. The infection rate in the unvaccinated group was 8.6% versus zero in the booster vaccinated group (Fisher's exact test -value = .004). Our findings demonstrated the potential effectiveness of the booster BCG vaccine, specifically the booster in preventing Covid-19 infections in an elevated-risk healthcare population.

MeSH

Vaccines, Vaccination, Covid-19, Tuberculosis, Immunity, Infections

Cited by

• BCG vaccination in health care providers and the protection against COVID-19. J Clin Invest, 2021
• Effectiveness of Bacille Calmette-Guerin vaccination policies in reducing infection and mortality of COVID-19: a systematic review. Glob Health Res Policy, 2022
• Mucosal COVID-19 vaccines: Risks, benefits and control of the pandemic. World J Virol, 2022
• SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments. Front Immunol, 2021
• A Multi-Center, Randomised, Double-Blind, Placebo-Controlled Phase III Clinical Trial Evaluating the Impact of BCG Re-Vaccination on the Incidence and Severity of SARS-CoV-2 Infections among Symptomatic Healthcare Professionals during the COVID-19 Pandemic in Poland-First Results. Vaccines (Basel), 2022
• Old vaccines for new infections: Exploiting innate immunity to control COVID-19 and prevent future pandemics. Proc Natl Acad Sci U S A, 2021
• COVID-19 and Beyond: Exploring Public Health Benefits from Non-Specific Effects of BCG Vaccination. Microorganisms, 2021
• Natural unblinding of BCG vaccination trials. Vaccine, 2021
• Influenza and Pneumococcal Vaccination and the Risk of COVID-19: A Systematic Review and Meta-Analysis. Diagnostics (Basel), 2022
• BCG vaccination potential for COVID-19: an analytical approach. Hum Vaccin Immunother, 2021
• Mucosal immune responses to infection and vaccination in the respiratory tract. Immunity, 2022
• Evaluating the Protective Effect of Intravesical Bacillus Calmette-Guerin against SARS-CoV-2 in Non-Muscle Invasive Bladder Cancer Patients: A Multicenter Observational Trial. Cancers (Basel), 2023
• Update on the COVID-19 Vaccine Research Trends: A Bibliometric Analysis. Infect Drug Resist, 2021
• Large-Scale Structure-Based Screening of Potential T Cell Cross-Reactivities Involving Peptide-Targets From BCG Vaccine and SARS-CoV-2. Front Immunol, 2022
• Revisiting the potential role of BCG and MMR vaccines in COVID-19. Sci Prog, 2022
• Trained Immunity, BCG and SARS-CoV-2 General Outline and Possible Management in COVID-19. Int J Mol Sci, 2023
• Mucosal immunity and vaccination strategies: current insights and future perspectives. Mol Biomed, 2025
• BCG Vaccination: A potential tool against COVID-19 and COVID-19-like Black Swan incidents. Int Immunopharmacol, 2022
• On BCG Vaccine Protection from COVID-19: A Review. SN Compr Clin Med, 2021
• BCG and SARS-CoV-2-What Have We Learned? Vaccines (Basel), 2022